U.S. markets open in 4 hours 53 minutes
  • S&P Futures

    4,475.25
    +1.00 (+0.02%)
     
  • Dow Futures

    34,793.00
    +44.00 (+0.13%)
     
  • Nasdaq Futures

    15,519.25
    +1.50 (+0.01%)
     
  • Russell 2000 Futures

    2,228.10
    +0.20 (+0.01%)
     
  • Crude Oil

    72.06
    -0.55 (-0.76%)
     
  • Gold

    1,762.80
    +6.10 (+0.35%)
     
  • Silver

    23.03
    +0.24 (+1.06%)
     
  • EUR/USD

    1.1780
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.48
    +0.30 (+1.65%)
     
  • GBP/USD

    1.3808
    +0.0011 (+0.08%)
     
  • USD/JPY

    109.9400
    +0.2220 (+0.20%)
     
  • BTC-USD

    47,997.27
    -101.58 (-0.21%)
     
  • CMC Crypto 200

    1,226.13
    -7.15 (-0.58%)
     
  • FTSE 100

    7,050.46
    +22.98 (+0.33%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

CCXI LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of ChemoCentryx, Inc. Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York—(Newsfile Corp. - June 22, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders ChemoCentryx, Inc. (NASDAQ: CCXI).

CLICK HERE FOR MORE DETAILS:

https://claimyourloss.com/securities/chemocentryx-inc-loss-submission-form/?id=17079&from=5

Affected shareholders purchased shares of CCXI between November 26, 2019 and May 6, 2021

Shareholders interested in representing the class of wronged shareholders have until July 6, 2021 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, ChemoCentryx, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88266